BIOMAT Database Logo BIOMAT Database Logo

[Proceedings: Clinical experience with administration of 2 alpha, 3 alpha- epithio-5 alpha-androstan-17 beta- yl, 1-methoxy-cyclopentyl ether (10364-S) in breast diseases]. 1974

M Izuo, and T Okada, and K Suemasu, and M Fujimori

UI MeSH Term Description Entries
D001941 Breast Diseases Pathological processes of the BREAST. Endocrine Breast Diseases,Breast Disease,Breast Disease, Endocrine,Breast Diseases, Endocrine,Disease, Breast,Disease, Endocrine Breast,Diseases, Breast,Diseases, Endocrine Breast,Endocrine Breast Disease
D004987 Ethers Organic compounds having two alkyl or aryl groups bonded to an oxygen atom, as in the formula R1–O–R2.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000731 Androstanes The family of steroids from which the androgens are derived.
D013440 Sulfides Chemical groups containing the covalent sulfur bonds -S-. The sulfur atom can be bound to inorganic or organic moieties. Sulfide,Thioether,Thioethers,Sulfur Ethers,Ethers, Sulfur
D045930 Anabolic Agents These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. Anabolic Effect,Anabolic Effects,Agents, Anabolic,Effect, Anabolic,Effects, Anabolic

Related Publications

M Izuo, and T Okada, and K Suemasu, and M Fujimori
[Proceedings: Anti-estrogen action of 2 alpha, 3 alpha-epithio-5 alpha-androstan-17 beta-yl, 1-methoxy-cyclopentyl ether (10364-S)].
February 1974, Nihon Naibunpi Gakkai zasshi,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
[Proceedings: Clinical evaluation of a new protein anabolic steroid, 2 alpha-3 alpha-epithio-5 alpha-androstan-17 beta-yl, 1, -methoxycyxlopentyl ether (10364-S)].
February 1974, Nihon Naibunpi Gakkai zasshi,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
Proceedings: 2 alpha, 3 alpha-epithio-5alpha-androstan-17beta-YL 1-methoxy-cyclophenyl ether (10364-S), a new orally active anabolic-androgenic steroid.
January 1974, Japanese journal of pharmacology,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
2Alpha, 3alpha-epithio-5alpha-androstan-17beta-YL 1-methoxycyclopentyl ether (10364-S), a new orally active anti-estrogenic steroid.
June 1974, Steroids,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
2 alpha, 3 alpha-epithio-5 alpha-androstan-17 beta-OL in the treatment of chronic mastopathy.
September 1968, Endocrinologia japonica,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
Syntheses of 1-alpha,2-alpha- and 1-beta,2-beta-epithio-A-nor-5-alpha-androstan-17-beta-ol and related compounds.
December 1967, Chemical & pharmaceutical bulletin,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
[Clinical experience with 17-beta-hydroxy-17-alpha-methyl-2-oxa-5-alpha-androstan-3-one (oxandrolone)].
March 1969, Horumon to rinsho. Clinical endocrinology,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
2 ,3 - Epithio-5 -androstan-17 -ol in the treatment of advanced breast cancer.
April 1973, Cancer,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
Effect of 5 alpha-androstan-17 beta-ol-3-one (DHT) and 5 alpha-androstan-3 alpha, 17 beta-diol (3 alpha-diol) on ether-induced prolactin secretion.
July 1982, Experientia,
M Izuo, and T Okada, and K Suemasu, and M Fujimori
Metabolism of 5 alpha-androstane-3 beta,17 beta-diol to 17 beta-hydroxy-5 alpha-androstan-3-one and 5 alpha-androstan-3 alpha,17 beta-diol in the rat.
August 1979, Biochimica et biophysica acta,
Copied contents to your clipboard!